Skip to main content Skip to footer
Novakand Pharma
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Svenska
Start>News>Report>Interim

Interim

  • Interim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851

    28 August 2025

  • Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

    23 May 2025

  • Interim Report Fourth Quarter 2024, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

    21 February 2025

  • Interim Report Third Quarter 2024, July 1 – September 30 Kancera AB (publ.), org.no. 556806-8851

    15 November 2024

  • Interim Report Second Quarter 2024, April 1 – June 30, Kancera AB (publ.), org.no. 556806-8851

    23 August 2024

  • Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

    17 May 2024

  • Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

    23 February 2024

  • Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851

    17 November 2023

  • Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851

    18 August 2023

  • Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851

    19 May 2023

+46 (0)8 5012 60 80Nanna Svarts väg 4, 171 65 Solna, Sweden

Content

  • Home
  • About us
  • Pipeline
  • Therapeutic areas
  • Investors

Shortcuts

  • Press Releases
  • Financial Reports
  • Financial Calendar
  • Website Policy

Copyright © 2025 Novakand AB. All Rights Reserved. Design by Clavis Communications